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In healthy human skin host defense molecules such as antimicrobial peptides (AMPs) contribute to skin immune
homeostasis. In patients with the congenital disease ectodermal dysplasia (ED) skin integrity is disturbed and as a
result patients have recurrent skin infections. The disease is characterized by developmental abnormalities of
ectodermal derivatives and absent or reduced sweating. We hypothesized that ED patients have a reduced skin
immune defense because of the reduced ability to sweat. Therefore, we performed a label-free quantitative
proteome analysis of wash solution of human skin from ED patients or healthy individuals. A clear-cut difference
between both cohorts could be observed in cellular processes related to immunity and host defense. In line with
the extensive underrepresentation of proteins of the immune system, dermcidin, a sweat-derived AMP, was
reduced in its abundance in the skin secretome of ED patients. In contrast, proteins involved in metabolic/
catabolic and biosynthetic processes were enriched in the skin secretome of ED patients. In summary, our
proteome profiling provides insights into the actual situation of healthy versus diseased skin. The systematic
reduction in immune system and defense-related proteins may contribute to the high susceptibility of ED
patients to skin infections and altered skin colonization.
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INTRODUCTION
Human skin represents the largest organ of our body and
provides the epithelial barrier to the external environment.
Although the skin is continuously challenged by an immense
number of potential pathogens, it rarely develops infections.
This is achieved by an effective skin innate immune response
in healthy people. Essential defense mediators in the skin are
inflammatory cytokines, chemokines, and antimicrobial pep-
tides (AMPs), which are expressed constitutively or after an
inflammatory stimulus, mainly by keratinocytes in the stratum
corneum. In addition, cells present in the skin, such as
neutrophils (Gallo and Nakatsuji, 2011), mast cells (Di
Nardo et al., 2003), T cells (Agerberth et al., 2000), eccrine
sweat glands (Schittek et al., 2001), hair bulb cells (Muller
et al., 2003), and sebocytes (Nagy et al., 2006; Lee et al.,
2008), are also able to produce AMPs. These AMPs either
directly kill the pathogens or activate immune cells in the sub-
epithelial layers to clear invading pathogens (Schroder and
Harder, 2006; Weindl et al., 2007). It has been shown that in
some human skin diseases recurrent skin infections are
associated with reduced AMP production by keratinocytes
(Schittek et al., 2008; Yamasaki and Gallo, 2008; Zanger
et al., 2009; Simanski et al., 2010; Zanger et al., 2010;
Schittek, 2011).
Sweat produced by eccrine sweat glands, which are
distributed over the whole body, is constantly secreted and
covers the skin’s surface. Peptides processed from the dermci-
din precursor are the most abundant AMPs in eccrine sweat
with a broad spectrum of antimicrobial activity (Schittek et al.,
2001). We showed previously that patients with atopic derma-
titis, who are characterized by aberrant Staphylococcus aureus
colonization of the skin, have a reduced amount of dermcidin-
derived peptides in their sweat. This correlated with an
impaired ability of sweat to eradicate bacteria on the skin of
these patients (Rieg et al., 2005; Schittek, 2011). This indicates
that eccrine sweat does not only have a function in
temperature regulation but also in the skin immune defense.
The capability of thermoregulation and infection defense by
sweat is severely limited in patients suffering from ectodermal
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dysplasia (ED) (Schneider et al., 2011). ED is a complex group
of inherited disorders that share common developmental
abnormalities of two or more of the following: hair, teeth,
nails, sweat glands, and other ectodermal structures. Until
now, more than 160 different ED symptoms have been
described clinically and around 30 genes are known to be
involved in ED pathogenesis (Irvine, 2009). The most frequent
form of ED is hypohidrotic ED (HED), also called the Christ–
Siemens–Touraine syndrome, which can be inherited in an
X-linked, autosomal recessive or autosomal dominant manner
(Mikkola, 2009; Knaudt et al., 2012). HED is characterized by
sparse scalp hair, few and conical teeth, and absent or
reduced sweating due to missing or nonfunctional sweat
glands (Mikkola and Thesleff, 2003). Patients generally
present with clinical symptoms resembling atopic dermatitis,
such as dry skin, erythema, eczema, bacterial skin infection,
mostly with S. aureus, increased fragility of the skin and
hyperkeratosis (Knaudt et al., 2012). On a molecular level,
HED has been associated with various X-linked mutations of
ectodysplasin, which is a tumor necrosis factor ligand within
the nuclear factor B essential modulator (NEMO) pathway. An
intact NEMO regulatory protein appears to be critical for both
ectodermal development and proper immune function
signaling (Schimke et al., 2013).
In the present study, we used a label-free quantitative
proteomic approach to determine the relative abundance of
proteins present on the skin of healthy individuals and HED
patients. As eccrine sweat is a rich source of functionally
important cellular proteins, we hypothesized that patients who
suffer from HED have a different protein spectrum on the skin
compared with healthy individuals. Their missing or reduced
ability to sweat might influence the clinical skin symptoms,
such as recurrent skin infections. Especially, the AMP dermci-
din, which is only produced by eccrine sweat glands, should
be present in limited amounts in ED patients. We provide, to
our knowledge previously unreported, a global analysis of the
composition of secreted or shedded proteins on the skin in
healthy individuals and ED patients.
RESULTS
Global proteome characterization of the secretome of healthy
and ED skin
For a comparative analysis of proteins found on the skin of
healthy individuals versus HED patients, we performed a
label-free quantitative proteomic analysis of samples of skin
wash solution from three independent replicates of a pool from
each six ED patients and six healthy volunteers, respectively.
In total, 544 proteins could be identified. Of the 544 proteins,
61 proteins were exclusively identified in healthy volunteers,
whereas 100 proteins were uniquely identified in ED patients.
A total of 383 proteins were identified in both ED patients and
healthy volunteers (Figure 1a). Of the 383 overlapping
proteins, 81 proteins were significantly differentially expressed
(Benjamini Hochberg false discovery rateo0.05). Among
those 81 proteins, 42 proteins were elevated in their abun-
dance in ED patients, whereas 39 proteins were decreased in
ED patients (Figure 1b). A list of all identified and quantified
proteins is present in Supplementary Table S1 online. Proteins
not significantly differentially expressed are present in
Supplementary Table S2 online.
Biological significance of identified proteins
To understand the functional significance of the identified
proteins, we performed analyses of gene ontology for bio-
logical function classification using the ‘‘Database for annota-
tion, visualization, and integrated discovery’’ (DAVID)
(DAVID Bioinformatics Resources 6.7, National Institute of
Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD)
that systematically identifies functional classes enriched in the
gene lists (Dennis et al., 2003; Huang da et al., 2009). The
analysis revealed major differences in the proteins that were
differentially or exclusively expressed in healthy volunteers
(Figure 2a) or ED patients (Figure 2b). Cellular processes
significantly enriched in the secretome of healthy individuals
mainly included categories related to immunity and host
defense (55%), proteolysis (26%) and development (17%).
The main category of immunity and host defense included
proteins significantly enriched in the subcategories of defense
response (P¼ 1.19E–05), inflammatory response (P¼ 1.31E–
03), response to stress (P¼4.10E–03), and wounding
(P¼ 5.44E–03) (Figure 2a). Tissue development represents
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Figure 1. Label-free mass spectrometry analyses of pooled skin wash solution
from 3 6 healthy volunteers and 3 6 hypohidrotic ectodermal dysplasia
(HED) patients. (a) Venn diagram showing the overlap between the numbers of
proteins quantitatively identified from healthy individuals and HED patients.
Of the 383 overlapping proteins statistically significant differentially expressed
proteins (Benjamini Hochberg false discovery rateo0.05) are shown in the
volcano plot. (b) Volcano plot analysis reveals that 81 proteins are significantly
differentially expressed. Among the 81 proteins, 42 proteins were significantly
elevated in HED patients (indicated by red dots), whereas 39 proteins
were significantly decreased in HED patients (indicated by green dots).
ED, ectodermal dysplasia; HED, hypohidrotic ectodermal dysplasia.
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the most enriched subcategory included in developmental
processes (1.92E–03; data not shown).
With exception of the functional categories response to
stress and response to wounding, none of these cellular
processes found in healthy individuals were significantly
enriched in the secretome of ED patients (Figure 2b). In ED
patients, proteins of cellular processes related to metabolism/
catabolism (40%), biosynthetic processes (25%), and
nucleic acid metabolism (13%) were significantly enriched
(Figure 2b). The group of proteins in the functional cluster
metabolic/catabolic processes included proteins in the sub-
categories of carbohydrate, glucose, alcohol, hexose, and
monosaccharide metabolism/catabolism (Figure 2b). The cate-
gory of genes involved in biosynthetic processes included
mainly the subcategories of different metabolic processes
(organic and carboxylic acid metabolic process, cellular
ketone, and amine metabolic process), as well as nitrogen
compound metabolic process (data not shown). Therefore, the
category of biosynthetic processes (25%) overlaps with the
category of metabolic/catabolic processes (40%) and cellular
metabolic processes (3%), indicating that in ED patients
mainly proteins involved in metabolic and catabolic activity
are overrepresented.
Proteins involved in tissue development are reduced in the skin
secretome of ED patients
ED patients are impaired in several ectodermally derived
structures such as the skin, hair, nails, teeth, and sweat glands.
Accordingly, in the skin secretome of healthy individuals, we
observed an enrichment of proteins involved in developmen-
tal processes, which is rigorously reduced in ED patients
(Figure 2a and b). Especially, the categories epidermis and
ectoderm development were significantly reduced in ED
patients (P¼ 2.46E–03 and P¼3.45E–03 in healthy indivi-
duals vs. P¼4.57E–02 and P¼ 5.78E–02 in ED patients).
Thereby, the P-values imply the significance of being
enriched, which is almost 10-fold lower in ED patients (see
also Supplementary Table S3 and S4 online). By zooming into
the single protein level multiple proteins involved in epider-
mal differentiation and morphogenesis, e.g., kallikrein-7,
kallikrein-5, protein-glutamine gamma-glutamyltransferase,
hornerin, and isoform 4 of extracellular matrix protein 1, were
either exclusively or significantly enriched in the skin secre-
tome of healthy individuals (Figure 4a and b; Supplementary
Figure S2 online). In contrast, kallikrein-8 and the fatty acid–
binding protein, both are known to be highly expressed in
psoriatic skin, were significantly enriched in ED patients
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Figure 2. Gene ontology analysis for biological functions of proteins identified in the human skin secretome. Gene ontology analysis for biological functions of
proteins identified in skin wash solutions of healthy individuals (a) and of HED patients (b) using Database for annotation, visualization, and integrated discovery
software (DAVID). (a) Cellular processes represented by the proteins, which were exclusively and significantly elevated in healthy individuals. (b) Cellular
processes represented by the proteins, which were exclusively and significantly elevated in HED patients. The bars represent  log10(P) values, where P represents
the significance of each cellular process being enriched by exclusively monitored proteins and differentially expressed proteins. ED, ectodermal dysplasia; HED,
hypohidrotic ectodermal dysplasia.
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(Figure 3b). Furthermore, an increased amount of several types
of keratins could be observed for ED patients (Figure 3a and
b). Thus, the high abundance of proteins involved in tissue
development in healthy individuals indicates an intact
renewal of the healthy skin, whereas the presence of proteins
normally found in psoriatic skin, together with several types of
keratins might be due to the dry skin in ED patients, which is
often clinically characterized with erythema, wrinkling, ero-
sions, increased fragility of skin, or plantar hyperkeratosis
(Knaudt et al., 2012).
Proteins involved in host defense are reduced in the skin
secretome of ED patients
Considering the 45 most abundant proteins exclusively identi-
fied in healthy individuals, it is striking that many identified
proteins were related to cellular processes involved in immunity
and host defense. Several of the identified proteins are proteases
(i.e., antileukoproteinase, neutrophil elastase, carboxypeptidase,
and cathepsin G), AMPs/proteins (i.e., bactericidal/permeability-
increasing fold–containing family A member 1, bactericidal/
permeability-increasing fold–containing family B member 1,
azurocidin, and mucin-7), or have a role in the humoral
immune response (i.e., complement component C7, several Ig
molecules; Figure 4a and Supplementary Figure S2 online).
Among the top 40 most abundant proteins significantly
elevated in healthy individuals compared with ED patients
(Figure 4b) again several proteins were involved in local host
defense. As already noted for proteins exclusively present in
healthy individuals (Figure 4a), proteins with antimicrobial
activity and/or proteolytic activity were significantly enriched in
the secretome of healthy skin (dermcidin, cathepsin D, lysozyme
C, ribonuclease 7, and S100 proteins A8 and A9; Figure 4b). In
accordance with the proteomic data (Figures 4b and 5f), we
could validate by ELISA that the AMP ribonuclease 7 was
significantly elevated in healthy individuals compared with ED
patients (including all types of ED forms; P¼0.004; Figure 5g).
Dermcidin is specifically reduced in the secretome of ED
patients
In the proteomic analysis, we found that the AMP dermcidin is
significantly underrepresented in wash solutions of ED patients
compared with healthy individuals (median of label-free
Proteins exclusively monitored in ED patients
Dystrophin (P11532) Phosphoglycerate mutase 1 (P18669)
Glutathione S-transferase P (P09211)
Oligoribonuclease, mitochondrial (Q9Y3B8)
Extracellular glycoprotein lacritin (Q9GZZ8)
Heme-binding protein 2 (Q9Y5Z4)
Elongation factor 2 (P13639)
Alpha-1-acid glycoprotein 2 (P19652)
Phosphoglucomutase-2 (Q96G03)
Rho GDP-dissociation inhibitor 2 (P52566)
UPF0556 protein (Q969H8)
Keratin, type II cytoskeletal 4 (P19013)
Junction plakoglobin (P14923)
Ras-related protein Rab-7a (P51149)
NADH-cytochrome b5 reductase 2 (Q6BCY4)
DNA damage-binding protein 1 (Q16531)
Glutathione synthetase (P48637)
Purine nucleoside phosphorylase (P00491)
Malate dehydrogenase, mitochondrial (P40926)
78 kDa glucose-regulated protein (P11021)
Coatomer subunit beta (P35606)
D-tyrosyl-tRNA(Tyr) deacylase 1 (Q8TEA8)
Isoform 2 of kallikrein-8 (O60259-2)
Cystatin-SN (P01037)
Profilin-1 (P07737)
Cystatin-SA (P09228)
lsoform 3 of malate dehydrogenase, cytoplasmic (P40925-3)
Endonuclease domain-containing 1 protein (O94919)
WW domain-binding protein 2 (O969T9)
ADP-sugar pyrophosphatase (A6NFX8)
Keratin, type II cytoskeletal 1b (Q7Z794)
Protein S100-A6 (P06703)
Alpha-2-HS-glycoprotein (C9JV77)
Filamin-A (P21333)
Calmodulin (H0Y7A7
0
LFQ intensity
1x1007 2x1007 3x1007
Isoform 3 of interleukin-1 receptor antagonist protein (P18510-3)
Keratin, type II cuticular Hb2 (Q9NSB4)
Keratin, type II cuticular Hb5 (P78386)
Keratin, type II cutoskeletal 73 (Q86Y46)
Phosphoglycerate kinase 1 (P00558)
Keratin, type I cuticular Ha5 (Q92764)
Keratin, type I cuticular HA3-II (Q14525)
Coactosin-like protein (Q14019)
Galectin-related protein (Q3ZCW2)
Keratin, type I cuticular Ha6 (076013)
Nuclear transport factor 2 (P61970)
N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 (O95865)
Ribosyldihydronicotinamide dehydrogenase [quinone] (P16083)
Cystatin-B (P04080)
Keratin, type II cuticular Hb3 (P78385)
Triosephosphate isomerase (P6074)
Lipocalin-1 (P31025)
Gamma-glutamylcycotransferase (O75223)
Alpha-amylase 1 (P04745)
Arginase-1 (P05089)
Fatty acid-binding protein, epidermal (Q01469)
Alpha-enolase (P0733)
Serotransfrrin (P02787)
Catalase (P04040)
Serpin B8 (P50452)
Phosphatidyethanolamine-binding protein 1 (P30086)
Cystatin-S (P01036)
Transaldolase (P37837)
Serpin B13 (Q9UIV8)
Hemoglobin subunit alpha (P69905)
Plasminogen activator inhibitor 2 (P05120)
Leukocyte elastase inhibitor (P30740)
PITH domain-containig protein 1(Q9GZP4)
Saposin-D (B1AVU8)
0
LFQ intensity
2x1008 4x1008 6x1008
0 2x1007 4x1007
LFQ intensity LFQ intensity
6x1007 8x1007 0 2x1006 4x1006 6x1006 8x1006 1x1007
Isoform 2 of glucose-6-phosphate isomerase (P06744-2)
Proteins significantly elevated in ED patients
Figure 3. The most intense proteins identified in the skin secretome of ED patients. The top 30 most intense proteins exclusively monitored in HED patients (a) or
the top 40 most intense proteins significantly elevated in HED patients (b) identified by label-free LC-MS/MS analyses. Blue bars represent the protein intensity from
healthy individuals and red bars represent the protein intensity from HED patients. Mean±SD. ED, ectodermal dysplasia; HED, hypohidrotic ED; LC-MS/MS,
liquid chromatography–mass spectrometry; LFQ, label-free quantification.
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quantification intensity in healthy individuals 1.18 108 and
median of label-free quantification intensity in ED patients
3.04 106 (Figure 5a)). We could validate this result in wash
solutions of the 18 patients used for proteomic analysis by
ELISA (Sagawa et al., 2003) (Figure 5b). To validate these
findings in a larger cohort, we determined the concentration of
dermcidin in wash solution of human skin of 51 healthy
individuals and 46 ED patients (including all types of ED
forms) by ELISA. Whereas skin wash solutions in both groups
did not differ in their total protein content (P¼0.3551;
Figure 5c), the abundance of dermcidin-derived peptides
in ED patients was significantly reduced (P¼o0.0001;
Figure 5d). Furthermore, we could show that the amount of
dermcidin-derived peptides is independent of the total protein
concentration in both cohorts (Figure 5e). In summary, using
two quantitative methods we show that dermcidin is specifi-
cally reduced in the skin secretome of ED patients.
Treatment of mice with a dermcidin containing ointment
reduces S. aureus colonization
As ED patients frequently suffer from bacterial skin infections
mainly caused by S. aureus, we speculate that the level of
dermcidin might influence the development of skin infections.
To investigate whether dermcidin alone will lead to a reduc-
tion in colony-forming units, mouse skin was epicutaneously
infected with S. aureus and treated either with a dermcidin
containing ointment or with a placebo twice daily. A sig-
nificant reduction in colony-forming units could be observed
24 hours after the beginning of treatment with a dermcidin-1-
containing ointment (30mg ml1) compared with mice treated
with a placebo. This effect could be observed either for
bacteria that were loosely attached to the epidermal surface,
as well as for bacteria that were invaded into the skin
(Figure 6). Seventy-two hours after the beginning of treatment
again a reduction in colony-forming units could be observed.
However, this decrease in S. aureus cells did not reach
statistical significance (Figure 6). Thus, dermcidin in the form
of an ointment led to a reduction in S. aureus load, which
might be a new therapeutic option to prevent skin infections in
ED patients.
DISCUSSION
Cutaneous hallmarks of ED are depigmentation, scaling,
atrophy, or hyperkeratosis (Itin et al., 1993b). Furthermore,
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Figure 4. The most intense proteins identified in the skin secretome of healthy individuals. The top 30 most intense proteins exclusively monitored in healthy
individuals (a) and the top 40 most intense proteins significantly elevated in healthy individuals (b) identified by label-free LC-MS/MS analyses. Blue bars represent
the protein intensity from healthy individuals and red bars represent the protein intensity from HED patients. Mean±SD. BPI, bactericidal/permeability-increasing;
ED, ectodermal dysplasia; HED, hypohidrotic ED; LC-MS/MS, liquid chromatography–mass spectrometry; LFQ, label-free quantification.
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the body hair is often diminished (Itin et al., 1993a) and sweat
glands are reduced or totally absent (Itin and Fistarol, 2004;
Schneider et al., 2011). Using a label-free quantitative
proteome analysis we compared the abundance of
proteins present on human skin from HED patients and
healthy individuals. Our analyses by label-free liquid
chromatography–mass spectrometry were paralleled by a
quantitative ELISA using an antibody directed against dermci-
din. Our investigations revealed a specifically reduced secre-
tion of dermcidin, because total protein concentration did not
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ectodermal dysplasia; LC-MS/MS, liquid chromatography–mass spectrometry; LFQ, label-free quantification; NS, not significant; RNase 7, ribonuclease 7.
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differ in wash solutions of human skin from ED patients versus
healthy individuals. This is in analogy to patients with atopic
dermatitis, who are characterized by aberrant S. aureus
colonization of the skin, having a reduced amount of
dermcidin-derived peptides in their sweat. This lack of anti-
microbial defense correlated with an impaired ability of sweat
to eradicate bacteria on the skin of these patients (Rieg et al.,
2005; Schittek, 2011). In contrast, Rieg and colleagues
recently reported in a correlation study that patients with
recurrent S. aureus skin and soft tissue infections and healthy
people have a comparable level of dermcidin-derived peptides
in their sweat (Rieg et al., 2014). The high abundance of
dermcidin in the secretome of healthy individuals, which is
known to be exclusively expressed by eccrine sweat glands in
the skin (Rieg et al., 2004; Schittek, 2012), suggests that a
majority of the identified proteins in the skin secretome of
healthy individuals are derived from eccrine sweat. Indeed,
many proteins we identified have been described to be present
in human eccrine sweat as for example cathepsin D and
prolactin-inducible protein (Baechle et al., 2006; Raiszadeh
et al., 2012). Importantly, most of the proteins in the skin
secretome of healthy individuals were enriched in cellular
processes involved in immune defense and underrepresented
in the skin secretome of ED patients. In particular, proteins in
this functional group were mainly involved in local infection
defense, as for example the humoral immune response (Igs and
complement factors), protease activity, or antimicrobial
activity. This underlines the importance of host defense
molecules that are constantly present on the skin surface.
These mediators provide a protective environment resulting in
efficient constitutive defense against infections. To our
knowledge previously unreported, this study describing the
secretome of human skin gives a snapshot of proteins on the
epidermal barrier. In addition, the comparison of the
secretome of healthy individuals with that of ED patients
suffering from reduced sweating enables us to indirectly
evaluate the abundance of proteins on human skin derived
from eccrine sweat glands.
Several proteomic studies demonstrated that normal sweat
obtained from healthy volunteers contains proteolytic
enzymes, AMPs, as well as the proinflammatory cytokines
IL-1 and IL-8 (Dai et al., 2013). We could not find IL-8 in the
secretome of healthy individuals or ED patients, indicating
that this interleukin is not very abundant on human skin.
Interestingly, the only cytokine significantly differentially
expressed was IL-37 (Figure 4a), which is known to suppress
innate inflammatory and immune responses by reducing IL-1a
and IL-6 among others (Sharma et al., 2008; Nold et al.,
2010). IL-1a, IL-36b, and IL-36g have been identified,
however, without significantly different expression
(Supplementary Table S2 online).
In the skin secretome of ED patients, a decrease in proteins
involved in developmental processes was observed. Especially
for the categories ectoderm and tissue development a
rigorous reduction could be observed. This is in line with the
fact that ED patients have defects in their ectodermally derived
structures (Itin and Fistarol, 2004). By zooming into the single
protein level, proteins normally found in psoriatic skin were
highly expressed, indicating a disturbed renewal of the skin.
HED is often associated with an immunodeficiency syn-
drome with defective Ig production and bacterial skin infec-
tions. Indeed, Ig levels are reduced in the skin secretome of ED
patients, and these patients frequently suffer from S. aureus
skin infections (data not shown). In many HED patients, the
disease is caused by mutations in genes encoding proteins
involved in the activation of NF-kB), a transcription factor
pivotal for innate and adaptive immune responses, cell
adhesion, cell growth, apoptosis, and ectodermal develop-
ment (Schimke et al., 2013). It seems that in healthy
individuals the NF-kB signaling pathway is of importance for
expression of genes involved in immune responses, which is
lacking in ED patients. By this, the proteins involved in
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Figure 6. Treatment of C57BL/6 mice with a dermcidin (DCD)-1-containing ointment reduces S. aureus infection. Bacterial counts were determined from
recovered mouse skin 24 and 72 hours after the beginning of treatment either with a DCD-1-containing ointment (red squares) or with a placebo (blue squares).
Bacteria loosely attached to the epidermal surface were recovered simply by washing (a) and bacteria invaded into the skin’s surface were recovered by scraping
(b). Horizontal lines represent median amounts of colony-forming units (CFUs). Statistically significant differences between the treatment groups are indicated:
*Po0.01–0.05; **Po0.001–0.01; NS, not significant.
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immune responses are underrepresented in ED patients. As it
is known that ED is caused among others by mutations of
genes encoding for adhesion (Itin and Fistarol, 2004; South,
2004), we found a significant reduction in proteins involved in
cell–cell adhesion and cell–matrix adhesion in ED patients
(desmocollin-1, desmocollin-2, desmoglein-1, CD44 antigen,
and the Ly6/PLAUR domain–containing protein 3) (Figures 4a
and b). Desmosomal cadherins are important for the adhesion
of neighboring cell membranes. Furthermore, proteins
involved in the epidermis and tissue development are over-
represented in healthy individuals, which might be a sign of
epidermal renewal.
ED patients are clinically characterized by dry skin with
erythema, wrinkling, erosions, bacterial infection, increased
fragility of skin, or plantar hyperkeratosis (Knaudt et al., 2012).
They share many aspects with xerosis and mild-to-moderate
atopic dermatitis. Because of the hyperkeratosis it is not
astonishing that especially different types of keratins are
overrepresented in the skin secretome of ED patients.
Keratins are known to be involved in the differentiation and
survival of keratinocytes but also in inflammation and wound
healing (Roth et al., 2012; Lessard et al., 2013). The
overrepresentation of keratins in ED patients might either be
a symptom of the dry and erosive skin and hyperkeratosis or
are functionally relevant in mediating cutaneous immuno-
suppression. Together with the lower abundance of AMPs and
proteases in the secretome of ED patients the disturbed keratin
profile might make the skin prone for infections. Many AMPs
have to be post-proteolytically processed into their mature
form by proteases to gain full activity. For example cathepsin
D, which is known to cleave dermcidin into shorter peptides,
was similar to dermcidin itself, significantly elevated in its
abundance on healthy skin.
The external application of the DCD-1 ointment on S.
aureus infected mouse skin clearly demonstrated a reduction
in the bacterial load. Thus, indicating on a functional level
that DCD is an essential determinant of cutaneous immune
homeostasis. DCD in the form of an ointment might be a new
therapeutic option to alleviate and/or prevent skin infections in
ED patients. On the basis of the proteomic data, it would be
desirable to develop a DCD-1 ointment containing additional
AMPs/factors to limit S. aureus skin infection not only in ED
patients but also in patients with atopic dermatitis. As
ribonuclease 7 in addition to dermcidin was significantly
reduced in ED patients, as demonstrated by two independent
quantitatively approaches, this potent antimicrobial ribonu-
clease active especially against S. aureus (Harder and
Schroder, 2002) might be another missing factor that favors
skin infections in ED patients.
In summary, we describe a noninvasive method for the
determination of proteins in the skin secretome of healthy
individuals and patients suffering from ED. Using the liquid
chromatography–mass spectrometry approach, we identified a
comprehensive protein profile composed of proteins related to
cellular processes such as immunity and host defense in
healthy individuals and metabolic/catabolic and biosynthetic
processes in ED patients. Our investigations underscore the
power of proteomics to utilize quantitative molecular
techniques in the field of clinical medicine. One potential
outcome of this study is that identification of a more global
proteomic composition in normal skin may serve as the basis
for characterizing and comparing the skin proteomes from a
variety of disease states, which may lead to a more complete
understanding of the pathology of the disease eventually
helping to develop new therapeutic options.
MATERIALS AND METHODS
Study population and patients
Wash solution of human skin was collected from 46 ED patients (18
female and 28 male) registered in an ED network (Selbsthilfegruppe
Ektodermale Dysplasie e.V., Aichtal, Germany) and from 51 healthy
individuals (22 female and 29 male). The study was approved by the
local ethics (713/2013BO2), and all study participants gave written
informed consent. From each donor, wash solution was taken from
both hands and from one forearm and subsequently pooled. Samples
were frozen at  20 1C until further analysis.
Collection of wash solution of human skin and processing
Wash solution from each skin area was taken by incubation of the
skin with 3 ml of 1:10 diluted phosphate-buffered saline for 2 minutes
restricting the liquid flow by a truncated collection tube ofB5.7 cm2.
Subsequently, the wash solution was mixed with protease inhibitors
(Roche complete, Mannheim, Germany). Wash samples from human
skin were centrifuged for 5 minutes at 5,000 r.p.m. and supernatant
decanted in a new collection tube. For analysis, samples were
lyophilized and the lyophilisate was solved in 400ml H20. From each
sample the protein concentration was determined by the bicincho-
ninic acid test (Pierce, Bonn, Germany) as described by the
manufacturer. For proteome analysis, 100ml of the dissolved lyophi-
lisate of 3 6 HED patients and 3 6 healthy individuals, respec-
tively, were used and pooled.
Gene ontology
To determine gene ontological annotations for selected proteins, we
used the DAVID software (Dennis et al., 2003; Huang da et al.,
2009). The list of all identified categories is present in Supplementary
Tables S2 and S3 online.
Statistical methods
Statistical analysis was performed with the Prism 5.0 package
(GraphPad Software, San Diego, CA). DCD and total protein con-
centrations, determined by ELISA and the bicinchoninic acid assay,
were compared using two-sample t-tests. Po0.05 was considered to
be statistically significant.
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